Further studies on the metabolic effects of 9-beta-D-arabinofuranosyl-9-H-purine-6-thiol.
D000014:Abnormalities, Drug-Induced; D000818:Animals; D001377:Azaserine / Q000627:therapeutic use; D002286:Carcinoma, Ehrlich Tumor / Q000378:metabolism; D004273:DNA, Neoplasm / Q000096:biosynthesis; D005260:Female; D005964:Glucosyltransferases / Q000032:analysis; D007939:Leukemia L1210 / Q000188:drug therapy; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D015122:Mercaptopurine / Q000627:therapeutic use* / Q000633:toxicity; D051379:Mice; D009705:Nucleosides / Q000627:therapeutic use* / Q000633:toxicity; D010088:Oxidoreductases / Q000378:metabolism; D010770:Phosphotransferases / Q000032:analysis; D011247:Pregnancy; D011270:Pregnancy, Animal; D012510:Sarcoma 180 / Q000188:drug therapy*; D012513:Sarcoma, Experimental / Q000188:drug therapy
D004273:DNA, Neoplasm; D009705:Nucleosides; D001377:Azaserine; D015122:Mercaptopurine; D010088:Oxidoreductases; D005964:Glucosyltransferases; D010770:Phosphotransferases